

**Embargoed until August 25, 2018 at 11:00 CEST / 05:00 EST**

**MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG**

**Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode**

- *TRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients<sup>1</sup>*
- *83% of chronic heart failure patients are hospitalized at least once due to an acute heart failure episode<sup>2</sup>*
- *Outlook for patients in first 30 days following hospitalization is poor, with one in four re-admitted<sup>3</sup> during this vulnerable period and up to 10% likely to die<sup>4</sup>*
- *Entresto has been proven in the landmark PARADIGM-HF study to be superior to enalapril in reducing CV mortality, HF hospitalization and 30-day hospital readmission in heart failure patients with reduced ejection fraction<sup>5,6</sup>*

**Basel, August 25, 2018** - Data from the TRANSITION study presented today at the European Society of Cardiology (ESC) Congress in Munich, Germany has shown that Entresto® (sacubitril/valsartan) can be initiated early and safely in a wide range of heart failure patients with reduced ejection fraction (HFrEF) who have been stabilized after hospitalization due to an acute heart failure episode<sup>1</sup>. Patients involved in the study included those with no prior experience of Entresto or conventional HF therapies, as well as those with prior experience of conventional HF therapies<sup>1</sup>.

About half of all heart failure patients have reduced ejection fraction<sup>7</sup>, and optimizing treatment for these patients according to guidelines is critical to reduce the likelihood of another acute episode or dying<sup>8</sup>. However, there is often hesitancy to initiate a new treatment after a hospitalization as these patients are considered 'vulnerable' and unable to tolerate changes in their medication.

"In the weeks following an episode of acute heart failure, patients are very vulnerable and face a high risk of re-hospitalization and death," said Prof. Rolf Wachter, University Hospital Leipzig, Germany and study investigator. "The PARADIGM-HF study showed that sacubitril/valsartan reduces heart failure-related hospitalizations, re-hospitalization and death. TRANSITION shows that sacubitril/valsartan can be initiated early and safely in patients shortly after an acute heart failure episode, providing physicians with added confidence to optimize their care with innovative medicines in heart failure treatment."

In TRANSITION, the safety and tolerability of Entresto were assessed in HFrEF patients after they have been stabilized following an acute heart failure episode. Patients were randomized to initiate Entresto therapy either in the hospital (pre-discharge) or shortly after leaving the hospital (post-discharge)<sup>1</sup>. At 10 weeks, more than 86% of patients were receiving Entresto for 2 weeks or longer without interruption and about half of patients in the study achieved the primary endpoint which was a target dose of 200 mg of Entresto twice daily within 10 weeks in both groups<sup>1</sup>. The number of patients who met the primary and secondary endpoints was similar across both treatment arms<sup>1</sup>. The incidence of adverse events and discontinuations of

Entresto due to adverse events was also similar in both the in-hospital and the out-patient setting<sup>1</sup>.

“We are encouraged by the findings of TRANSITION which show that Entresto, the new standard of care in heart failure, can be safely initiated in recently hospitalized patients,” said Shreeram Aradhye, MD, Chief Medical Officer and Global Head, Medical Affairs, Novartis Pharmaceuticals. “Heart failure is a serious progressive disease with 83% of patients hospitalized at least once for an acute heart failure episode during the course of their condition. Hospitalization provides an opportunity for physicians to optimize heart failure treatment according to guidelines to reduce the likelihood of hospital readmission and death, reduce the burden of hospitalizations, and improve patient outcomes.”

### **About TRANSITION**

TRANSITION (NCT02661217) is a randomized, phase IV, multicenter, open-label, parallel-group study, which assessed the safety and tolerability of Entresto in 1,002 HFrEF patients, from 156 hospitals worldwide, after stabilization following hospitalization for acute heart failure, when treatment was started in hospital (pre-discharge) or shortly after leaving hospital (post-discharge)<sup>1,9</sup>. Patients were grouped based on their pre-admission treatment status: those who were receiving an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB), or those with no prior experience with an ACEI/ARB. Following screening and randomization to Entresto, the study comprised a 10 week treatment period followed by a 16 week follow-up phase. The primary and secondary endpoints were the number of patients achieving the target dose of Entresto of 200 mg twice daily (bid) at week 10 (regardless of previous dose interruption or down-titration), and number of patients maintaining 100 mg or 200 mg bid for at least two weeks leading to week 10 after randomization, respectively<sup>1,9</sup>. The study protocol took into account the needs of the practicing cardiologists, and enabled investigators to select the appropriate starting dose of Entresto and dose adjustments due to clinical circumstances, allowing for differences between international hospitals and healthcare settings<sup>9</sup>.

### **About Entresto**

Entresto is a twice-a-day medicine that reduces the strain on the failing heart. It does this by enhancing the protective neurohormonal systems (natriuretic peptide system) while simultaneously inhibiting the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS)<sup>10,11</sup>. Other common heart failure medicines, called angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), only block the harmful effects of the overactive RAAS. Entresto contains the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan<sup>10,12</sup>.

In Europe, Entresto is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction<sup>10</sup>. In the United States, Entresto is indicated for the treatment of heart failure (New York Heart Association class II-IV) in patients with systolic dysfunction<sup>12</sup>. It has been shown to reduce the rate of cardiovascular death, heart failure hospitalization and 30-day hospital readmission<sup>6</sup> compared to enalapril, to reduce the rate of all-cause mortality compared to enalapril<sup>5</sup>, and to improve aspects of health-related quality of life (including physical and social activities) compared to enalapril<sup>13</sup>. Entresto is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin receptor blocker (ARB)<sup>10,12</sup>. Approved indications may vary depending upon the individual country.

### **About Heart Failure and Hospitalization**

Heart failure (HF) is a serious progressive disease with debilitating symptoms. HF patients are at risk of a sudden worsening of the disease that requires urgent care in hospital and it is the number one reason for hospitalization in people over 65 years<sup>14</sup>. Of the 26 million people worldwide living with HF<sup>15</sup>, 83 percent of HF patients are hospitalized due to an acute HF episode at least once, and nearly half (43%) are hospitalized at least four times<sup>2</sup>. Every year,

there are approximately one million hospitalizations due to HF in the US and Europe<sup>16</sup>, and on average, a HF patient remains in hospital for five to 10 days<sup>17</sup>. Due to this, heart failure presents a major and growing health-economic burden that currently costs the world economy \$108 billion every year, which accounts for both direct and indirect costs<sup>18</sup>.

### **Disclaimer**

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

### **About Novartis**

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 125,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit <http://www.novartis.com>.

Novartis is on Twitter. Sign up to follow @Novartis at <http://twitter.com/novartis>  
For Novartis multimedia content, please visit [www.novartis.com/news/media-library](http://www.novartis.com/news/media-library)  
For questions about the site or required registration, please contact [media.relations@novartis.com](mailto:media.relations@novartis.com)

### **References**

1. Wachter R. *et al.*, Initiation of sacubitril/valsartan in hospitalized patients with heart failure with reduced ejection fraction after hemodynamic stabilization: Primary results of the TRANSITION study. Data presented at: ESC 2018, Aug 25-29; Munich, Germany.
2. Yancy CW. *et al.*, 2013 ACCF/AHA Guideline for the Management of Heart Failure, *J Am Coll Cardiol.* 2013; 62(16):e147-e239.

3. Dharmarajan K, Hsieh AF, Lin Z, *et al.*, Diagnoses and Timing of 30-Day Readmissions after Hospitalization For Heart Failure, Acute Myocardial Infarction, or Pneumonia. *JAMA*. 2013;309(4):355-363.
4. Bueno H, Ross JS, Wang Y, *et al.*, Trends in Length of Stay and Short-Term Outcomes among Medicare Patients Hospitalized for Heart Failure: 1993–2008. *JAMA*. 2010;303(21):2141-2147.
5. McMurray JJV., *et al.*, Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. *N Engl J Med* 2014; 371:993-1004.
6. Desai, AS., *et al.*, Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. *JACC* 2016;68(3):241-248.
7. Owan TE, Hodge DO, Herges RM, *et al.* Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med*. 2006;355:251-259.
8. Maggioni, AP., *et al.*, Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail*. 2013 Oct;15(10):1173-84.
9. Pascual-Figal D., *et al.*, Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. *ESC Heart Fail*. 2018 Apr;5(2):327-336.
10. EMA. Entresto (sacubitril/valsartan). Summary of product characteristics. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/004062/WC500197536.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf) [Last accessed: July 2018]
11. Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. *Drug Discov Today*. 2012;4: e131-139.
12. FDA. Entresto (sacubitril/valsartan). Highlights of prescribing information. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/207620Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf) [Last accessed: July 2018]
13. Chandra, A. *et al.*, The Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Heart Failure Patients: The PARADIGM-HF Trial. *JAMA Cardiol*. 2018;3(6):498-505.
14. Azad N, Lemay G. Management of chronic heart failure in the older population. *Journal of Geriatric Cardiology: JGC*. 2014;11(4):329-337.
15. Savarese G and Lund LH. Global Public Health Burden of Heart Failure *Card Fail Rev*. 2017 Apr; 3(1): 7–11.
16. Ambrosy A, Fonarow G, Butler J. *et al.*, The global health and economic burden of hospitalizations for heart failure. *J Am Coll Cardio*. 2014, 63 (12), 1123-33.
17. Ponikowski P. *et al.*, 2014. Heart failure. Preventing disease and death worldwide. Available at: [https://www.escardio.org/static\\_file/Escardio/Subspecialty/HFA/WHFA-whitepaper-15-May-14.pdf](https://www.escardio.org/static_file/Escardio/Subspecialty/HFA/WHFA-whitepaper-15-May-14.pdf) [Last accessed: July 2018]
18. Cook C, Cole G, Asaria P. *et al.*, The annual global economic burden of heart failure. *Int J Cardiol*. 2014.;171(3):368-76.

###

### Novartis Media Relations

Central media line: +41 61 324 2200  
E-mail: [media.relations@novartis.com](mailto:media.relations@novartis.com)

Eric Althoff  
Novartis Global Media Relations  
+41 61 324 7999 (direct)  
+41 79 593 4202 (mobile)  
[eric.althoff@novartis.com](mailto:eric.althoff@novartis.com)

Agnes Estes  
Novartis Cardio-Metabolic Communications  
+41 61 324 1986 (direct)  
+41 79 644 1062 (mobile)  
[agnes.estes@novartis.com](mailto:agnes.estes@novartis.com)

### Novartis Investor Relations

Central investor relations line: +41 61 324 7944  
E-mail: [investor.relations@novartis.com](mailto:investor.relations@novartis.com)

Central  
Samir Shah +41 61 324 7944  
Pierre-Michel Bringer +41 61 324 1065  
Thomas Hungerbuehler +41 61 324 8425  
Isabella Zinck +41 61 324 7188

North America  
Richard Pulik +1 212 830 2448  
Cory Twining +1 212 830 2417